Αποτελέσματα Αναζήτησης
1 Μαΐ 2023 · Overall, allogeneic NK transfer using PBMC-expanded NK cells appears promising in dogs with cancer, and pre-clinical and clinical data support the use of SC analysis as a valuable technique for biomarker identification and optimizing NK IT in dogs.
We aimed to compare bulk PBMC-derived NK cells versus NK cells expanded from CD5-depleted PBMCs, and then evaluate clinical and genomic characteristics of PBMC-expanded dog NK cells using both autologous and allogeneic NK products in first-in-dog clinical trials in dogs with cancer.
Within this framework, these guidelines offer the following sequential approach to managing each medically unique cancer case: diagnosis, staging, therapeutic considerations, careful attention to patient and personnel safety in handling chemotherapeutic agents, referral to an oncology specialty practice when appropriate, and a strong emphasis on...
22 Απρ 2024 · Here we define a protocol for single cell TCR sequencing that should enhance the utility of canine samples as they relate to the study of cancer and disease.
16 Απρ 2024 · Background: Natural killer (NK) cells are cytotoxic cells capable of recognizing heterogeneous cancer targets without prior sensitization, making them promising prospects for use in cellular immunotherapy. Companion dogs develop spontaneous cancers in the context of an intact immune system, representing a valid cancer immunotherapy model.
Adoptive cell transfer (ACT) is a burgeoning therapeutic modality within human immuno-oncology. Novel approaches towards ACT are being developed in the pre-clinical setting faster than they can be evaluated in human clinical trials.
6 Δεκ 2018 · This review summarizes the current status of canine cancer immunotherapies, with focus on autologous and allogeneic T-lymphocytes, as well as NK cells, and discusses potential initiatives that would allow therapies with canine immune cells to “catch up” with the advances in humans.
